Brief: Inmune Bio Announces FDA Alignment On Integrated Phase 2B/3 Registration Pathway For Xpro1595 In Early Alzheimer’S Disease
12/02/2026 12:25
Feb 12 (Reuters) - INmune Bio Inc INMB.O: INMUNE BIO ANNOUNCES FDA ALIGNMENT ON INTEGRATED PHASE 2B/3 REGISTRATION PATHWAY FOR XPRO1595 IN EARLY ALZHEIMER’S DISEASE Source text: ID:nGNEr9dKQ Further company coverage: INMB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview